Nectar Lifesciences Ltd.

NecLife

Ref: NLL\CS\2015- 54

March 3, 2015

1. National Stock Exchange of India Limited
   'G' Block, Exchange Plaza, Bandra Kurla Complex,
   Bandra (East), MUMBAI – 400 051.

2. BSE Limited
   Phiroze Jeejeebhoy Towers, Dalal Street,
   MUMBAI – 400 001.

Sub. Investors Press Release

Dear Sirs,

Please find attached herewith an Investor Press release that ***"Nectar Lifesciences Ltd. bags European cGMP approval for Oral and injectable Cephalosporin APIs."***

This is for your information and necessary dissemination to investors.

Thanking you,

Yours faithfully,
For Nectar Lifesciences Limited

Dinesh Dua
Chief Executive Officer & Director

NECTAR LIFESCIENCES LIMITED
CIN: L24232PB1995PLC016664
Regd. Office: Village Saidpura, Tehsil – Derabassi, Distt. S.A.S Nagar (Mohali) Punjab – 140507, India.
Ph: 01762-308000, 308001; Fax: 01762-308135, Email: sunderlal@neclife.com, Website: www.neclife.com
Corporate Office: Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

Nectar Lifesciences Ltd. bags European cGMP approval for Oral and injectable Cephalosporin APIs.

Chandigarh, 3 Mar, 2015

Nectar Lifesciences Limited (NecLife), the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has touched yet another significant milestone by receiving **European cGMP ("Current Good Manufacturing Practices") approval for its Cephalosporin APIs' manufacturing facility in Dera Bassi, Punjab.**

NecLife has received the European cGMP compliance certification through successful inspection by the Portugal Authority - National Authority of Medicines and Health Products, INFARMED. This approval is valid for three years for calendar years 2015 to 2017. The INFARMED Certificate is accepted by all EU Health Authorities and by authorities of several other countries. The facility is already approved by various international regulatory agencies such as US-FDA, MCC – South Africa, PMDA – Japan, OGYI-Hungary and KFDA- South Korea.

Highly lucrative EU market for Cephalosporin's' is currently valued at USD 1.5 Bn. between injectable and oral molecules. NecLife has highest capacities globally of all the approved molecules in Cephalosporin's. This approval opens up very valuable market for NecLife for API's as well as formulations for which Unit-6 located in Baddi is already approved by the EU authority which is valid from July 2013 till July 2016. NecLife is committed to take leadership position in its line of products in Cephalosporin's' in Europe besides United States, Japan and other ROW countries.

Till date, NecLife has filed 42 Drug Master Files (DMFs) and 15 Abbreviated New Drug Applications (ANDAs). NecLife has very ambitious plan of filing multiple DMFs ANDAs/EU/ROW dossiers in US, EU and other rest of world markets in year 2015-16.

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NecLife, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). NecLife globally is one of the largest manufacturers of cephalosporin range of products which are exported to 55 countries across five continents. NecLife has a global leadership position in 3 oral molecules and 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab, and two in Baddi, Himachal Pradesh.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: dinesh.dua@neclife.com

Note: *This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.*